Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on GABA. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel lipase mutant enhances Pregabalin intermediate synthesis efficiency and purity. Cost-effective biocatalytic solution for pharmaceutical manufacturing supply chains.
Patent CN105602922A reveals efficient amidase catalysis for gabapentin intermediates. Achieve high purity and cost reduction in pharmaceutical intermediates manufacturing with scalable biocatalytic routes.
Patent CN118026867B details a high-efficiency chiral resolution for Mirogabalin intermediates, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN104402752A reveals high purity synthesis route. Offers significant cost reduction and supply chain reliability for global pharmaceutical intermediates manufacturing partners.
Patent CN104557583A reveals green quinidine catalysis for high-purity pharmaceutical intermediates ensuring cost reduction and supply chain reliability.
Patent CN112359036B discloses engineered nitrilase mutants for efficient synthesis of pregabalin chiral intermediates, offering significant cost reduction in API manufacturing.
Patent CN101585778A details a scalable route from S-(+)-leucine avoiding toxic azides. Ideal for reliable lyrica intermediate supplier sourcing and cost reduction.
Novel metal halide catalysis eliminates high-pressure hydrogenation risks. Delivers high-purity lactam compounds with significant cost reduction in API manufacturing and enhanced supply chain reliability for global partners.
Patent CN1438985A details a stereoselective route to gabapentin analogs using chiral enones, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.
Patent CN1675165A discloses a novel route for 1-(acyloxy)-alkyl carbamates of GABA analogs. Enhances bioavailability and simplifies manufacturing for reliable pharmaceutical intermediates supply.
Patent CN108456143A details a high-yield asymmetric route for Pregabalin intermediates ensuring supply chain stability and significant cost reduction for global pharmaceutical manufacturing.
Patent CN113804805A details a solvent-free method for synthesizing Pregabalin Impurity II. Achieve >99% purity for QC standards with reduced environmental impact.
Patent CN101848905A details a novel enantioselective route for (S)-pregabalin using D-mannitol, offering significant cost reduction and supply chain reliability for API manufacturing.
Novel route for GABA-T inhibitor precursor via lactam rearrangement offering cost reduction and scalable pharmaceutical intermediate manufacturing solutions.
Advanced hydrolysis method for high-purity gabapentin. Reduces toxic impurities and energy consumption. Ideal for API manufacturing scale-up.
Patent CN109851543B reveals a cost-effective route for S-pregabalin lactam using acidic oxides. Achieve >99% purity for pharmaceutical impurity standards.
Patent CN103073443B details a novel asymmetric synthesis for Pregabalin, offering improved yield and scalability for pharmaceutical supply chains.
Advanced asymmetric synthesis of pregabalin via CN103073443B. Offers cost reduction in pharmaceutical intermediate manufacturing and reliable supply chain solutions.
Patent CN103626668B reveals a novel resolution method for S-Pregabalin offering high purity and scalable supply chain advantages for pharmaceutical manufacturers.
Novel high-temperature water hydrolysis method enhances yield and reduces waste in gabapentin manufacturing, offering cost-effective supply chain solutions.